The relationship of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with erectile dysfunction (ED) has been investigated in a few studies. However, previous studies are limited by having a small participant number or minimal adjustment for potential confounding factors including testosterone and metabolic syndrome. Therefore, the current data are insufficient to support routine screening of ED in men with CP/CPPS or CP/ CPPS in men with ED.
INTRODUCTION AND OBJECTIVES:
The relationship of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) with erectile dysfunction (ED) has been investigated in a few studies. However, previous studies are limited by having a small participant number or minimal adjustment for potential confounding factors including testosterone and metabolic syndrome. Therefore, the current data are insufficient to support routine screening of ED in men with CP/CPPS or CP/ CPPS in men with ED.
METHODS: A prospective cross-sectional study was conducted that included 8,261 men. The National Institutes of HealthChronic Prostatitis Symptom Index (NIH-CPSI), and the International Index of Erectile Function-5 (IIEF) were used for assessment of symptoms. Symptoms were classified as a "mild prostatitis-like symptom" if respondents reported perineal or ejaculatory pain and had a NIH-CPSI pain score of !4 and <8; the symptoms were classified as "moderate to severe" if the pain score was !8 according to previous reports. Moderate to severe ED was defined as IIEF <12. A full metabolic work-up and serum testosterone level checks were also performed. We then investigated the relationship using statistical analysis.
RESULTS: The mean age was 50.4AE5.5 years. The mean testosterone level was 613 ng/dL (21.3 nmol/L). In total, 2,205 (24.9%) men had prostatitis-like symptoms (NIH-CPSI pain score of !4 and perineal or ejaculatory pain), and 618 (7.0%) men had moderate to severe symptoms (NIH-CPSI pain score of !8). Additionally, 1,041 men (12.6%) were classified as demonstrating moderate to severe ED (IIEF < 12). The IIEF score was found to have a significant negative correlation with the NIH-CPSI pain domain score (correlation coefficient [ -0.198 ; P < 0.001). After adjusting for age, metabolic syndrome status, and testosterone level, there was no change in the negative correlation between the NIH-CPSI pain domain score and IIEF score (Beta [ -0.395; P < 0.001). After adjusting for age, testosterone level, and metabolic syndrome, the odds ratio (OR) for moderate to severe ED significantly increased with the severity of pelvic pain (mild prostatitis-like symptoms, OR for moderate to severe ED: 2.557, 95% confidence interval: 2.092-3.125; moderate to severe symptoms, OR for moderate to severe ED: 5.164: 95% confidence interval: 4.433-6.016).
CONCLUSIONS: ED and chronic prostatitis-like symptoms are significantly and independently correlated with each other. The severity of prostatitis-like symptoms is also related to ED. Based on our data, we suggest routine screening for CP/CPPS in men with ED and ED in men with CP/CPPS.
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MP40-21 HIGHER FREE TESTOSTERONE PREDICTS FASTER POTENCY RECOVERY AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY
Farouk M. El-Khatib*, Linda Huynh, Maxwell Towe, Faysal A. Yafi, Thomas Ahlering, Orange, CA INTRODUCTION AND OBJECTIVES: Sexual dysfunction remains a significant problem for many men post robot-assisted radical prostatectomy. Low testosterone (T) is a well-known cause of sexual dysfunction. The present study seeks to assess whether low preoperative free testosterone (FT) reduces potency recovery for men following RARP.
METHODS: The study group included men with preoperative International Index of Erectile Function (IIEF-5) scores 22-25. Prospective data was entered for 442 men undergoing RARP by a single surgeon. Potency was defined as two affirmative answers to "erections adequate for penetration" and "were the erections satisfactory" using self-administered validated questionnaires at 3, 9 and 15 months post-RARP. FT values were prospectively collected and calculated pre-RARP and only men who answered the questionnaire at 3 and 15 months were included. Men with preoperative low FT (< 5.1 ng/dL) were compared to men with normal values. Logistic regression was used to adjust for significant covariates.
RESULTS: Of 442 men, 75 (17.0%) had preoperative FT< 5.1 ng/dL (low), 75 (17.0%%) had preoperative FT between 5.1 and 7 ng/dL (middle) and 62 (14.0%) had FT > 7 ng/dL (high). In the low group, 56.0% (42/75), 74.3% (55/74) and 81.3% (61/75) were potent at 3, 9 and 15 months, respectively. In the middle group, 58.7% (44/75), 82.7% (62/75) and 88.0% (66/75) were potent at 3, 9 and 15 months respectively. In the high group, 58.1% (36/62), 80.3% (49/61) and 90.3% (56/62) were potent at 3, 9 and 15 months respectively.
Throughout recovery, the low group had lower rates of sexual function recovery compared to both middle and high groups. For men with FT level below the 25th percentile, 15 month potency rate was 81.2% (39/48) compared to 90.3% (56/62) in men with FT > 7ng/dL. CONCLUSIONS: FT threshold <5.1 ng/dL was predictive of decreased return of potency at 3, 9 and 15 months post-RARP. These patients should be considered for preoperative testosterone replacement therapy.
